Carregant...
Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
BACKGROUND. Cancer immunotherapy targeting immune checkpoint inhibitors (ICIs) has been shown to be a promising strategy in the treatment of various malignancies. Despite the proven efficacy and tolerability of ICIs based on 113 clinical trials globally, data regarding the pharmacokinetic (PK) and p...
Guardat en:
| Publicat a: | Oncologist |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons, Inc.
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6394776/ https://ncbi.nlm.nih.gov/pubmed/30819827 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-IO-S1-s03 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|